Trials / Recruiting
RecruitingNCT06961214
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 960 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Depemokimab | Depemokimab as a sterile liquid formulation will be administered. |
| DRUG | Placebo | Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2029-08-21
- Completion
- 2029-08-21
- First posted
- 2025-05-07
- Last updated
- 2026-04-09
Locations
159 sites across 15 countries: United States, Argentina, Australia, Austria, Bulgaria, Czechia, Germany, Greece, Israel, Italy, Latvia, New Zealand, Romania, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06961214. Inclusion in this directory is not an endorsement.